Page 71 - ARNM-3-3

Advances in Radiotherapy
& Nuclear Medicine Software impact in Ho dosimetry
166

Conflict of interest doi: 10.3390/cancers17111841

The authors declare that they have no competing interests. 4. Reinders MTM, Smits MLJ, Roekel C, Braat AJAT.
Holmium-166 microsphere radioembolization of hepatic
Author contributions malignancies. Semin Nuclear Med. 2019;49(3):237-243.

Conceptualization: Rita Albergueiro, João Santos doi: 10.1053/j.semnuclmed.2019.01.008
Formal analysis: All authors 5. Stella M, Braat AJAT, Lam MGEH, Jong HWAM, Rooij R.
Investigation: All authors Gamma camera characterization at high holmium-166
Methodology: Rita Albergueiro, João Santos activity in liver radioembolization. EJNMMI Phys.
Writing–original draft: Rita Albergueiro 2021;8(1):22.
Writing–review & editing: Rafael Silva, João Santos doi: 10.1186/s40658-021-00372-9

Ethics approval and consent to participate 6. Stella M, Braat AJAT, Rooij R, Jong HWAM, Lam MGEH.
Holmium-166 radioembolization: Current status and future
The study was approved by the IRB of Santo António prospective. Cardiovasc Intervent Radiol. 2022;45(11):1634-
University Hospital Center, with reference number 1645.
2025-050 (043-CAC/043-CE). The IRB approved a waiver doi: 10.1007/s00270-022-03187-y
of informed consent for participation in the study due to
its retrospective and observational nature. All patients 7. Drescher R, Seifert P, Gühne F, et al. Radioembolization with
had previously provided written informed consent for the holmium-166 polylactic acid microspheres: Distribution of
therapeutic procedures included in this analysis. residual activity in the delivery set and outflow dynamics
during planning and treatment procedures. J Endovas Ther.
Consent for publication 2021;28(3):452-462.
The study was approved by the IRB of Santo António doi: 10.1177/1526602821996719
University Hospital Center, with reference number 2025- 8. Smits MLJ, Elschot M, van den Bosch MA et al. In
050 (043-CAC/043-CE). vivo dosimetry based on SPECT and MR imaging of
166 Ho-microspheres for treatment of liver malignancies.
Availability of data J Nucl Med. 2013;54(12):2093-2100.
Data that support the findings of the study are available doi: 10.2967/jnumed.113.119768
from the corresponding author on reasonable request. 9. Hobbs RF, Baechler S, Senthamizhchelvan S, et al. A gamma
camera count rate saturation correction method for whole-
Further disclosure body planar imaging. Phys Med Biol. 2010;55(3):817-831.
Part of the set of findings has been presented at EANM’24 doi: 10.1088/0031-9155/55/3/018
congress held at Hamburg, Germany, on October 10. Danieli R, Milano A, Gallo S, et al. Personalized dosimetry
19-23, 2024. in targeted radiation therapy: A look to methods, tools and

References critical aspects. J Pers Med. 2022;12(2):205.
doi: 10.3390/jpm12020205
1. Rumgay H, Arnold M, Ferlay J, et al. Global burden of
primary liver cancer in 2020 and predictions to 2040. 11. Cassano B, Miseo L, Ungania S, et al. Dosimetric study
J Hepatol. 2022;77:1598-1606. on radioembolization with 166 Ho poly L-lactic acid
microspheres: Dead time effects on prediction power.
doi: 10.1016/j.jhep.2022.08.021
EJNMMI Phys. 2025;12:64.
2. Wang ZG, He ZY, Chen YY, Gao H, Du XL. Incidence and doi: 10.1186/s40658-025-00779-8
survival outcomes of secondary liver cancer: A Surveillance
Epidemiology and End Results database analysis. Transl 12. Sjögreen-Gleisner K, Flux G, Bacher K, et al. EFOMP
Cancer Res. 2021;10(3):1273-1283. policy statement NO. 19: Dosimetry in nuclear
medicine therapy - Molecular radiotherapy. Phys Med.
doi: 10.21037/tcr-20-3319
2023;116:103166.
3. Sólymos P, Rédei M, Turan C, et al. Holmium-166 doi: 10.1016/j.ejmp.2023.103166
radioembolization is a safe and effective locoregional
treatment for primary and secondary liver tumors: 13. Reinders MTM, Braat AJAT, van Erpecum KJ, et al.
A systematic review and meta-analysis. Cancers (Basel). Holmium-166 radioembolisation dosimetry in HCC. Eur J
2025;17(11):1841. Nucl Med Mol Imaging. 2025;52:993-1003.

Volume 3 Issue 3 (2025) 63 doi: 10.36922/ARNM025220023